These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 1793290)

  • 1. [Antimicrobial activity of pefloxacin in comparison with other quinolones].
    Darenkov AF; Kotliarova GA; Kondrat'eva EM
    Antibiot Khimioter; 1991 Nov; 36(11):24-6. PubMed ID: 1793290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of pefloxacin compared with five other quinolones on nalidixic acid-resistant proteae species.
    Piccolomini R; Cellini L; Allocati N; Di Girolamo A; Selan L; Scazzocchio F
    Chemioterapia; 1988 Oct; 7(5):287-91. PubMed ID: 3224396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The in vitro activity of ofloxacin, pefloxacin and ciprofloxacin against various gram negative bacteria isolated from urinary tract infections].
    Tunçkanat F; Yuluğ N
    Mikrobiyol Bul; 1988; 22(3):187-92. PubMed ID: 3252111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of pefloxacin activity against recent clinical isolates.
    Lembo M; Covelli B; Nani E; Lavitola A
    J Chemother; 1991 Jan; 3 Suppl 1():51-3. PubMed ID: 12041785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of the in vitro activity of 6 quinolones on Pseudomonas sp].
    Lesage D; Delisle-Mizon F; Vergez P; Daguet GL
    Pathol Biol (Paris); 1985 May; 33(5):412-5. PubMed ID: 3162141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Activity of 5 fluoroquinolones on hospital Gram-negative bacilli with different sensitivities to pefloxacin].
    Aubert G; Puech C; Lucht F; Loboguerrero M; Denis M; Dorche G
    Pathol Biol (Paris); 1989 Oct; 37(8):881-7. PubMed ID: 2515519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in vitro activity of ciprofloxacin, ofloxacin and pefloxacin against resistant clinical isolates.
    Periti P; Mazzei T; Nicoletti P
    Chemioterapia; 1987 Apr; 6(2):75-8. PubMed ID: 3474081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Susceptibility to norfloxacin of some bacterial strains causing urinary infections].
    Tuchiluş C; Poiată A; Bădicuţ I; Buiuc D
    Rev Med Chir Soc Med Nat Iasi; 2005; 109(2):383-6. PubMed ID: 16607805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In vitro determination of the sensitivity of mycobacteria to fluoroquinolones].
    Dailloux M; Petitpain N; Henry C; Weber M
    Pathol Biol (Paris); 1989 May; 37(5):346-9. PubMed ID: 2780092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of the antimicrobial activity of pefloxacin (1589 RB), nalidixic acid and flumequin (author's transl)].
    Thabaut A; Durosoir JL
    Pathol Biol (Paris); 1982 Jun; 30(6):394-7. PubMed ID: 6810283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of pefloxacin compared to that of quinolones and other antimicrobial agents.
    Neu HC; Chin NX; Labthavikul P; Saha G
    Chemioterapia; 1984 Aug; 3(4):235-41. PubMed ID: 6241847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparative in vitro susceptibility of clinical bacterial isolates to pefloxacin and 14 antibiotics].
    Dolna I; Ruczkowska J; Chomontowicz M
    Przegl Lek; 1992; 49(7):213-5. PubMed ID: 1297147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of postantibiotic effects and postantibiotic effects of sub-inhibitory concentrations of quinolones and aminoglycosides on phospholipase C of Pseudomonas aeruginosa.
    Hybenová D; Majtán V
    Pharmazie; 1997 Feb; 52(2):157-9. PubMed ID: 9122276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [In vitro activity of new quinolones against Mycoplasma pathogenic to humans].
    Renaudin H; Quentin C; de Barbeyrac B; Bebear C
    Pathol Biol (Paris); 1988 May; 36(5):496-9. PubMed ID: 3136430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mechanisms of resistance to quinolones and current level of sensitivity of clinically important microorganisms to ofloxacin].
    Sidorenko SV; Rezvan SP; Makarova RA; Makarov AN; Kozlova NS; Ogneva NS; Korolev IuS; Gladin DP
    Antibiot Khimioter; 1996; 41(9):33-8. PubMed ID: 9005782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro study of staphylococci susceptibility to gatifloxacin.
    Tuchiluş C; Poiată A; Buiuc D
    Rev Med Chir Soc Med Nat Iasi; 2007; 111(2):516-9. PubMed ID: 17983195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Sensitivity of Yersinia pseudotuberculosis to pefloxacin].
    Zaĭtseva EA; Shubin FN; Besednova NN
    Antibiot Khimioter; 1995 Jul; 40(7):22-4. PubMed ID: 8645054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Activity of fluoroquinolones studied on a model of suppurative meningoencephalitis caused by Pseudomonas aeruginosa in mice].
    Padeĭskaia EN; Mnatsakanian VE
    Antibiot Khimioter; 1991 Jul; 36(7):25-8. PubMed ID: 1953184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of in vitro activities of the fluoroquinolones to their in vivo efficacies.
    Fernandes PB; Swanson RN
    Drugs Exp Clin Res; 1988; 14(6):375-8. PubMed ID: 3145851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro activity of quinolones against different species of staphylococci of recent clinical isolation.
    Rabagliati AM; Fiorio P; Cavallo R; Mills V; Penna R
    J Chemother; 1991 Jan; 3 Suppl 1():176-8. PubMed ID: 12041759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.